Journal
MATERIALS TODAY COMMUNICATIONS
Volume 20, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.mtcomm.2019.100554
Keywords
Kefiran cryogels; Diclofenac; Drug delivery system; Scaffolds; Tissue engineering
Categories
Funding
- Fundacao para a ciencia e a Tecnologia (FCT) from Portugal [CEECIND/00111/2017, SFRH/BPD/94277/2013, SFRH/BPD/117492/2016]
- FCT [M-ERA-NET/0001/2014, IF/01285/2015]
- R&D Project KOAT -Kefiran exopolysaccharide: Promising biopolymer for use in regenerative medicine and tissue engineering - FCT [PTDC/BTMMAT/29760/2017 (POCI-010145-FEDER-029760)]
- European Regional Development Fund (FEDER)
- Operational Programme for Competitiveness and Internationalisation (POCI)
- Fundação para a Ciência e a Tecnologia [M-ERA-NET/0001/2014] Funding Source: FCT
Ask authors/readers for more resources
A Kefiran-based scaffold was developed using a freeze gelation technique, and its potential use for both drug delivery system and tissue engineering applications were investigated. This scaffold showed, through micro-computed tomography and scanning electron microscopy, high porosity (82.3 +/- 4.4%), thick pore walls (13.4 +/- 0.7 mu m), aerogel form with foam-like structure, and elastic behaviour (delta = 16 +/- 0.7 degrees). Moreover, the Kefiran scaffold degradation showed a delayed profile for over 28 days. The developed scaffold allowed a slow and sustained diclofenac release over two weeks, and the human Adipose-derived Stem Cells, cultured onto the Kefiran scaffold, were metabolically active after 72 h. Therefore, our research suggests that Kefiran cryogel could be a potential candidate for drug delivery of controlled bioactive molecules and tissue engineering scaffolding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available